Replies to post #76385 on Biotech Values

[rkrw]

If that's the case, obviously rdea can't license 806 prior to phase 2B without some sort of amended agreement with Valeant. Valeant has no rights to the gout program.

<<For the HIV program (as opposed to the gout program), this option may be moot insofar as RDEA does not plan to start a phase-2b trial without a partner.>>>